What is HC Wainwright’s Forecast for Brainsway Q2 Earnings?

Brainsway Ltd. Sponsored ADR (NASDAQ:BWAY) – Research analysts at HC Wainwright boosted their Q2 2026 earnings per share (EPS) estimates for shares of Brainsway in a research note issued to investors on Tuesday, May 26th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings of $0.10 per share for the quarter, up from their prior forecast of $0.08. HC Wainwright has a “Buy” rating and a $17.00 price target on the stock. The consensus estimate for Brainsway’s current full-year earnings is $0.30 per share. HC Wainwright also issued estimates for Brainsway’s Q3 2026 earnings at $0.13 EPS, Q1 2027 earnings at $0.14 EPS, Q2 2027 earnings at $0.15 EPS, Q3 2027 earnings at $0.19 EPS, Q4 2027 earnings at $0.21 EPS and FY2027 earnings at $0.69 EPS.

Several other research firms also recently commented on BWAY. Zacks Research downgraded shares of Brainsway from a “strong-buy” rating to a “hold” rating in a research report on Monday, May 11th. Weiss Ratings raised Brainsway from a “hold (c)” rating to a “buy (b-)” rating in a report on Friday, April 24th. Finally, Wall Street Zen downgraded Brainsway from a “buy” rating to a “hold” rating in a research note on Saturday, May 16th. Three analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $16.00.

Brainsway Trading Up 5.2%

Shares of BWAY stock opened at $15.89 on Wednesday. The firm has a fifty day simple moving average of $14.87 and a two-hundred day simple moving average of $12.00. Brainsway has a 12 month low of $5.01 and a 12 month high of $17.35. The firm has a market capitalization of $636.20 million, a PE ratio of 45.40 and a beta of 1.23.

Brainsway (NASDAQ:BWAY) last released its quarterly earnings data on Wednesday, May 13th. The company reported $0.12 EPS for the quarter, beating the consensus estimate of $0.05 by $0.07. Brainsway had a return on equity of 12.28% and a net margin of 15.68%.The firm had revenue of $15.53 million during the quarter, compared to the consensus estimate of $14.63 million.

Institutional Trading of Brainsway

A number of hedge funds have recently bought and sold shares of the business. Harel Insurance Investments & Financial Services Ltd. bought a new position in Brainsway in the 1st quarter valued at $40,000. Raymond James Financial Inc. bought a new position in Brainsway during the second quarter valued at about $85,000. Bank of America Corp DE bought a new position in Brainsway during the third quarter valued at about $107,000. Royal Bank of Canada increased its holdings in Brainsway by 1,145.9% during the fourth quarter. Royal Bank of Canada now owns 8,410 shares of the company’s stock worth $160,000 after buying an additional 7,735 shares during the last quarter. Finally, Centiva Capital LP bought a new stake in Brainsway in the third quarter worth about $181,000. 30.11% of the stock is currently owned by institutional investors.

Brainsway Company Profile

Brainsway Ltd is a medical device company specializing in non-invasive neuromodulation therapies. Publicly traded on the NASDAQ under the symbol BWAY, the company develops and commercializes deep transcranial magnetic stimulation (Deep TMS) systems designed to treat a range of neuropsychiatric and neurological disorders. Brainsway’s technology aims to offer an alternative or complement to traditional pharmacological therapies by targeting precise brain regions with its patented coil designs.

The company’s flagship Deep TMS platform utilizes proprietary H-coil arrays engineered to reach deeper cortical structures than conventional TMS devices.